OctoPlus N.V. ("OctoPlus") (Euronext: OCTO), the drug deliverycompany, announces today that it has won an expansion of a drugdelivery technology evaluation contract with an existing client, aglobal pharmaceutical company. In 2008 and 2009 OctoPlus performedpreliminary feasibility work for this client and with the resultsfrom these studies the client has decided to proceed with theevaluation of OctoPlus' technology for a product candidate in itspipeline.

In October last year OctoPlus announced a strategic focus ondeveloping controlled release versions of existing or new drugs forclients, in addition to providing general formulation development andclinical material manufacturing. This is the fourth compound in 2009for which OctoPlus will work on a controlled release formulation.

Under the contract announced today, OctoPlus will evaluate thefeasibility of a controlled release formulation that combines theclient's product candidate with OctoPlus' proprietary drug deliverytechnology. If the evaluation is successful, the contract mayprogress to a full process development, manufacturing and licensingagreement.

For further information, please contact:Rianne RoukemaCorporate Communications:telephone number +31 (71) 524 1071 or send an e-mail to Investor Relationsat IR@octoplus.nl.

About OctoPlus

OctoPlus is a product-oriented biopharmaceutical company committed tothe creation of improved pharmaceutical products that are based onOctoPlus' proprietary drug delivery technologies and have fewer sideeffects, improved patient convenience and a better efficacy/safetybalance than existing therapies. Rather than seeking to discovernovel drug candidates through early stage research activities,OctoPlus focuses on the development of long-acting, controlledrelease versions of known protein therapeutics, other drugs, andvaccines on behalf of its clients.

The clinically most advanced product incorporating our technology isBiolex Therapeutics' lead product Locteron®, a controlled releaseformulation of interferon alpha for the treatment of chronichepatitis C. Locteron is being manufactured for Biolex Therapeuticsby OctoPlus and is currently in Phase IIb clinical studies.

In addition, OctoPlus is a leading European provider of advanced drugformulation and clinical scale manufacturing services to thepharmaceutical and biotechnology industries, with a focus ondifficult-to-formulate active pharmaceutical ingredients.

OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under thesymbol OCTO. For more information about OctoPlus, please visit ourwebsite www.octoplus.nl.

This document may contain certain forward-looking statements relatingto the business, financial performance and results of OctoPlus andthe industry in which it operates. These statements are based onOctoPlus' current plans, estimates and projections, as well as itsexpectations of external conditions and events. In particular thewords "expect", "anticipate", "predict", "estimate", "project","plan", "may", "should", "would", "will", "intend", "believe" andsimilar expressions are intended to identify forward-lookingstatements. We caution investors that a number of important factors,and the inherent risks and uncertainties that such statementsinvolve, could cause actual results or outcomes to differ materiallyfrom those expressed in any forward-looking statements. In the eventof any inconsistency between an English version and a Dutch versionof this document, the English version will prevail over the Dutchversion.

This announcement was originally distributed by Hugin. The issuer issolely responsible for the content of this announcement.

Click here for the press release in PDF:http://hugin.info/137076/R/1340023/320130.pdf

Copyright © Hugin AS 2009. All rights reserved.